Marte F. van der Bijl

Marte F. van der Bijl

Auto-generated profile, based on publicly available information

Marte F. van der Bijl

Department of Cardiology, Cardiovascular Institute, Erasmus MC, University Medical Center , Doctor Molewaterplein 40, Rotterdam 3015 GD

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 October 2022 in BMC Women's Health
Verified
Journal Article
Open access
PDF file
LKLili L. Kókai
Lili L. Kókai
MBMarte F. van der Bijl
Marte F. van der Bijl
Martin HaggerMartin Hagger
Martin Hagger
DCDiarmaid T. Ó Ceallaigh
Diarmaid T. Ó Ceallaigh
KRKirsten I.M. Rohde
Kirsten I.M. Rohde
AWAnne I. Wijtzes
Anne I. Wijtzes
Women with prior severe preeclampsia are at an increased risk for cardiovascular diseases later in life compared to women who had a normotensive pregnancy. The objective of this study was to assess their needs and preferences regarding app-based cardiovascular health promotion. Patients (n = 35) of the Follow-Up PreEClampsia Outpatient Clinic (FUPEC), Erasmus MC, the Netherlands, participated in an anonymous online survey. The main outcomes under study were women’s needs for health behavior promotion, and their preferences with respect to intervention delivery. Descriptive statistics were used to evaluate needs, and thematic analysis was used to analyze preferences. Women’s primary need for health behavior promotion pertained to their fat and sugar intake and physical activity; for some, to their mental health (practices), fruit and vegetable intake, salt intake, and water intake; and for a few, to their alcohol and tobacco use. Most women preferred an app-based intervention to include, in descending order: the tracking of health-related metrics, an interactive platform, the use of behavior change strategies, the provision of information, and personalization. Cardiovascular health promotion targeting women with prior severe preeclampsia should feel relevant to its audience. App-based interventions are likely to be well received if they target fat and sugar intake and physical activity. These interventions should preferably track health-related metrics, be interactive, contain behavior change strategies, provide information, and be personalized. Adopting these findings during intervention design could potentially increase uptake, behavior change, and behavior change maintenance in this population.

28 April 2026 in European Heart Journal
Verified
Journal Article
Open access
PDF file
MBMarte F van der Bijl
Marte F van der Bijl
NSNiels Tjeerd Benjamin Scholte
Niels Tjeerd Benjamin Scholte
JOJulie A E van Oortmerssen
Julie A E van Oortmerssen
JLJeanine elisabeth roeters Roeters van Lennep
Jeanine elisabeth roeters Roeters van Lennep
ASAstrid Schut
Astrid Schut
EBEric Boersma
Eric Boersma
Women remain underrepresented in heart failure (HF) trials, raising concerns about potential undetected sex-specific differences in treatment efficacy. This study assesses sex differences in the primary efficacy endpoint of HF treatments and examines whether the proportion of women enrolled in a trial influences (variations in) treatment effect estimates. A systematic search was conducted up to 21 March 2025, including randomized controlled trials (RCTs) (≥100 patients) evaluating pharmacological HF treatments vs. placebo or usual care, with clinical events as the primary outcome. Sex differences in the primary outcome were assessed using a random-effects meta-analysis of the reported relative effect measures (REM) and pooled estimates. For key clinical outcomes, meta-regression analyses were performed to examine the association between the proportion of women enrolled and sex differences in REMs, as well as the overall REMs without separating sex. Of 5749 screened publications, 139 RCTs met inclusion criteria, with 292 027 patients (28.1% women). Based on 78 RCTs that reported sex-stratified treatment effects, pooled analysis showed no difference in treatment efficacy between women and men (delta ln[REM] 0.00; 95% confidence interval (CI) −0.04 to 0.03; P = .85; I2 = 4.1%). Meta-regression found no association between the proportion of women and sex differences in REM (78 RCTs, P = .25), overall efficacy (139 RCTs, P = .24), or other clinical outcomes. These findings suggest that pharmacological efficacy in HF does not differ by sex and that historical female underrepresentation in trials is unlikely to have masked important sex differences. Nonetheless, improving sex balance in HF trials remains essential for societal and ethical reasons.

22 January 2026 in European Heart Journal
Verified
Journal Article
Closed access
SISanne Peters, The George Institute
Sanne Peters, The George Institute
MWMark Woodward
Mark Woodward
HRHester M Den Ruijter
Hester M Den Ruijter
MZMira G P Zuidgeest
Mira G P Zuidgeest
OBOtavio Berwanger
Otavio Berwanger
EBEric Boersma
Eric Boersma
Randomized controlled trials (RCTs) represent the gold standard for establishing the efficacy of new interventions. Yet, RCTs are often conducted in selected populations, not representative of those at risk for or living with the disease. This lack of representativeness has raised concerns about the generalizability of RCT results to those populations not (adequately) represented in RCTs, in particular in the absence of evidence on potential differences in treatment effects across population subgroups. In the field of cardiovascular disease, women are often underrepresented in RCTs relative to disease burden. The present paper seeks to define representative participation of women in RCTs. Trial data from two cardiovascular trials, the ADVANCE trial and the LoDoCo2 trial, are used to illustrate sample size requirements for (i) achieving representative participation, (ii) achieving representative contribution to knowledge gained, and (iii) assessing whether treatment effects are the same or different in men and women (i.e. sex * treatment interactions). Achieving representative participation and representative contribution to knowledge gained requires relatively small increases in sample size and is mainly driven by sex differences in disease rates. However, sample size requirements for RCTs powered to assess sex differences in treatment effects are unfeasibly large. Hence, while efforts to enhance representative trial participation should continue, as RCTs provide the cornerstone for guideline recommendations and clinical decision-making, these should be complemented by mechanistic studies to provide insights in possible treatment interactions and inform optimal treatment for both women and men.

4 March 2025 in Journal of the American Heart Association
Verified
Journal Article
Open access
MBMarte F. van der Bijl
Marte F. van der Bijl
JVJenny van der Veen
Jenny van der Veen
AFAernoud T.L. Fiolet
Aernoud T.L. Fiolet
EBEric Boersma
Eric Boersma
JCJan H. Cornel
Jan H. Cornel
JLJeanine elisabeth roeters Roeters van Lennep
Jeanine elisabeth roeters Roeters van Lennep

27 April 2022 in BMC Women's Health
Verified
Journal Article
Open access
PDF file
LKLili L. Kókai
Lili L. Kókai
MBMarte F. van der Bijl
Marte F. van der Bijl
Martin HaggerMartin Hagger
Martin Hagger
DCDiarmaid T. Ó Ceallaigh
Diarmaid T. Ó Ceallaigh
KRKirsten I. M. Rohde
Kirsten I. M. Rohde
AWAnne I. Wijtzes
Anne I. Wijtzes
Background: The objective of this study was to (1) qualitatively identify the perceived determinants of physical activity among women who have experienced severe preeclampsia, and (2) examine whether these determinants are consistent with the overarching processes outlined in the integrated behavior change (IBC) model, a novel model that describes physical activity as being a result of motivational, volitional, and automatic processes. Methods: Patients (n = 35) of the Follow-Up PreEClampsia (FUPEC) Outpatient Clinic, Erasmus MC, the Netherlands, participated in an anonymous online survey. The main outcomes under study were their perceived determinants of physical activity. Responses were analyzed using thematic analysis. Results: Thirteen themes emerged from the analysis. Six themes corresponded with motivational processes (future health, perceived ability, attitude, future reward or regret, physical appearance, and doing it for others), two with volitional processes (scheduling and planning), and two with automatic processes (affect and stress). Three themes were classified as environmental factors (time constraint, social support, and physical environment). Conclusions: A range of facilitating and hindering factors were described by women with prior severe preeclampsia as the determinants of their physical activity. These factors corresponded well with the overarching motivational, volitional, and automatic processes described in the IBC model. In addition, motivational and environmental factors beyond the IBC model were described. Addressing these perceived determinants could enhance the efficacy of physical activity interventions in this population. Tweetable abstract: Motivational, volitional, automatic, and environmental factors drive physical activity in women with prior severe preeclampsia.

4 February 2026 in European Heart Journal: Acute Cardiovascular Care
Verified
Journal Article
Open access
MBMarte F van der Bijl
Marte F van der Bijl
LPLotte A Paulis
Lotte A Paulis
HRHester M Den Ruijter
Hester M Den Ruijter
IWIris C D Westendorp
Iris C D Westendorp
ASAstrid Schut
Astrid Schut
EBEric Boersma
Eric Boersma
Aims: Female underrepresentation in clinical trials of acute coronary syndromes (ACS) may hinder the assessment of sex-based differences in the outcomes of long-term pharmacological therapy. The presence of these differences and their potential association with female representation in clinical trials remain unclear. Methods and results: A systematic search of Embase, Medline Ovid, and Cochrane Central was conducted through 1 July 2025, in accordance with the reporting standards of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Eligible randomized controlled trials (RCTs) compared long-term pharmacological therapy for ACS with placebo or standard care, included ≥1-year follow-up, and reported a clinical event as the primary outcome. Sex differences in treatment effects were analysed using a random-effects meta-analysis, while meta-regression was used to assess the association between the proportion of females in each trial and these differences. The main outcome was the sex difference in the relative effect measure (REM; mostly a hazard ratio) for the primary efficacy endpoint. Among 102 RCTs, female representation ranged from 10 to 52%. Forty-eight trials provided sex-stratified data. Pooled analysis showed no evidence of sex-related differences in efficacy: the mean difference in the log of the REM of males minus females was 0.00 (95% confidence interval, −0.05–0.05; P = 0.98; heterogeneity I² = 0%). Meta-regression indicated no relationship between female trial participation and sex-specific treatment effects. Conclusion: In RCTs of long-term pharmacological therapy after ACS, treatment efficacy was comparable between sexes, irrespective of sex distribution. These findings support current guidelines recommending equivalent long-term pharmacological strategies for secondary prevention in both sexes.